Section 17-1739.1-13 - Drug use review (PUR) board(a) An advisory drug use review board shall be appointed by the director of the department, and shall consist of:(1) The department's pharmacy consultant or medical consultant or both, shall serve as the drug use review coordinator(s);(2) Four persons licensed and actively engaged in the practice of medicine in the state;(3) Four persons licensed and actively practicing pharmacy in the state; and(4) One person actively practicing as a medical service representative in the state.(b) The term of each drug use review board member shall be three years and overlapped in such a way that expiration of terms shall not cause a total membership change.(c) A quorum shall consist of five board members; at least one of the five must be a physician or pharmacist.(d) The duties of the advisory drug use review board shall be to:(1) Meet when called by the chairperson;(2) Develop, review, and adapt criteria and standards for prospective and retrospective drug use review;(3) Make policy recommendations to the Hawaii medical assistance program in respect to confidentiality of patient related data, and all aspects of the drug use review program;(4) Decide on and monitor educational programs and interventions deemed appropriate based on potential therapeutic problems identified through the program; and(5) Determine the content and mix of educational programs and interventions for practitioners, designed to enhance the clinical appropriateness and cost effective use of prescription drugs with primary emphasis on therapeutic outcomes and quality of care.(e) The actions of the drug use review board shall be:(1) Subject to the approval of the department;(2) Remain confidential within the department; and(3) Be communicated to the specific providers affected.Haw. Code R. § 17-1739.1-13
[Eff 10/26/01] (Auth: HRS § 346-14; P.L. 101-508 ) (Imp: 42 C.F.R. §§456.1, 456.3 )